Bristol Expects FDA Advisory Committee Review Of Muraglitazar
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb expects FDA will hold an advisory committee meeting to discuss the application for its dual PPAR agonist muraglitazar